Biopharmaceutical benchmarks - 2003

被引：112

作者：

Walsh, G ^{[1
]}

机构：

[1] Univ Limerick, Ind Biochem Programme, Limerick, Ireland

来源：

NATURE BIOTECHNOLOGY | 2003年 / 21卷 / 08期

关键词：

D O I：

10.1038/nbt0803-865

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Since 2000, over a quarter of all new drugs approved have been biopharmaceuticals.

引用

页码：865 / 870

页数：6

共 11 条

[1] The delivery of antisense therapeutics [J].

Akhtar, S ;

Hughes, MD ;

Khan, A ;

Bibby, M ;

Hussain, M ;

Nawaz, Q ;

Double, J ;

Sayyed, P .

ADVANCED DRUG DELIVERY REVIEWS, 2000, 44 (01) :3-21

[2] Tissue engineering firms go under [J].

Bouchie, A .

NATURE BIOTECHNOLOGY, 2002, 20 (12) :1178-1179

[3] Cancer risk prompts US to curb gene therapy [J].

Check, E .

NATURE, 2003, 422 (6927) :7-7

[4]

HOLMER AF, 2002, NEW BIOTECHNOLOGY ME

[5] Synthetic DNA delivery systems [J].

Luo, D ;

Saltzman, WM .

NATURE BIOTECHNOLOGY, 2000, 18 (01) :33-37

[6] Gene therapy: Promises and problems [J].

Pfeifer, A ;

Verma, IM .

ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, 2001, 2 :177-211

[7] Key issues in non-viral gene delivery (Reprinted from Advanced Drug Delivery Reviews, vol 34, pg 3-19, 1998) [J].

Pouton, CW ;

Seymour, LW .

ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :187-203

[8]

Robinson K, 2002, BIOPHARM INT, V15, P20

[9]

THOMPSON L, 2000, FDA CONSUMER MAG SEP

[10] Biopharmaceutical benchmarks [J].

Walsh, G .

NATURE BIOTECHNOLOGY, 2000, 18 (08) :831-833

← 1 2 →